CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 840 enrolled
Drug / intervention
Bromfenac Ophthalmic Solution A +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01212471
NCT01212471Phase 3Completed

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Bausch & Lomb Incorporated·interventional·Posted Sep 30, 2010·Updated Sep 4, 2020

In Brief

A Phase 3 clinical trial evaluating Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, and 1 other intervention for Dry Eye Syndrome. Completed, enrolled 840 participants across 1 site.

Detailed Summary

A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2010
Enrollment StartSep 1, 2010
Primary CompletionAug 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.8 years ago

Interventions

Bromfenac Ophthalmic Solution Adrug

sterile ophthalmic solution

Bromfenac Ophthalmic Solution Bdrug

sterile ophthalmic solution

Placebo Comparatordrug

sterile ophthalmic solution